Constitutive expression and anticancer potency of a novel immunotoxin onconase-DV3

Oncology Reports
Miaonan SunDejun Sun

Abstract

Onconase is an RNase of the ribonuclease A superfamily that is purified from the Northern leopard frog (Rana pipiens). It targets several types of malignant tumors, digests cytoplasmic transfer RNA (tRNA), and causes tumor cell apoptosis. Onconase has been employed in clinical trials as an antitumor drug, and has revealed its valuable clinical activity in several types of tumors, particularly pleural mesothelioma. However, its inefficiency in targeting tumor cells and its non‑specific toxicity in normal tissues have diminished its clinical benefits. Furthermore, cyclization of the N-terminal glutamine residue (Gln), possesses more RNase activity than the structure of Met ahead of Glu in the N-terminal (99:1), which is more difficult for producing onconase by Pichia pastoris. Under the guidance of α-mating factor-pre (α-MF-pre) secretion signal, the secretion of the recombinant protein can reach a high level. In the present study, we constructed a constitutive expression vector for onconase-(DV3)2 (Onc-DV3) production in yeast Pichia pastoris with the GAP promoter, in which the Onc-DV3 gene is inserted downstream of the truncated Saccharomyces cerevisiae α-mating factor-pre (α-MF-pre) secretion signal. The immuno-RNase Onc-DV3 e...Continue Reading

References

Jul 21, 1999·Cancer Chemotherapy and Pharmacology·V M VasandaniC Sung
Apr 1, 2000·The Journal of Biological Chemistry·L E BretscherR T Raines
Feb 13, 2002·The Journal of Biological Chemistry·Shailendra K SaxenaRichard J Youle
Oct 7, 2003·Oncogene·Sylvie MénardElda Tagliabue
Dec 3, 2003·The Journal of Biological Chemistry·Vitaliy Y GorbatyukTai-huang Huang
Apr 9, 2004·Pharmaceutical Research·Eric L Snyder, Steven F Dowdy
Jul 13, 2004·Seminars in Cancer Biology·Fran Balkwill
Feb 11, 2005·Yeast·Sue Macauley-PatrickLinda M Harvey
Sep 3, 2005·Analytical Biochemistry·Külliki SaarUlo Langel
Nov 8, 2005·The Journal of Biological Chemistry·Melanie Rhee, Pamela Davis
Feb 25, 2006·The Journal of Biological Chemistry·Avvaru N Suhasini, Ravi Sirdeshmukh
Mar 22, 2006·Expert Opinion on Biological Therapy·Nick Pavlakis, Nicholas J Vogelzang
Nov 4, 2006·The Journal of Biological Chemistry·Marianela Perez-TorresCarlos L Arteaga
Mar 22, 2007·Journal of Cell Science·Montserrat RodríguezBruno Beaumelle
May 5, 2009·Journal of Controlled Release : Official Journal of the Controlled Release Society·Catherine L WatkinsArwyn T Jones
Nov 8, 2011·Applied Microbiology and Biotechnology·Leonardo M DamascenoCarl A Batt
Jan 17, 2012·Applied Biochemistry and Biotechnology·Xiaofeng WangYunjun Yan

❮ Previous
Next ❯

Citations

Dec 19, 2019·Frontiers in Immunology·Giovanni Gotte, Marta Menegazzi
Apr 25, 2018·Cancer Cell International·Miaonan SunMei Li
Nov 2, 2019·Journal of Pharmaceutical Sciences·Ji-Sun KimYong-Sung Kim

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis